BioNTech's Lung Cancer Drug Shows Promising Survival Results in Phase 3 Trial
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung cancer drug, gotistobart, demonstrated a clinically meaningful overall survival benefit in the Phase 3 PRESERVE-003 trial for patients with metastatic squamous non-small cell lung cancer who had previously received immunotherapy and chemotherapy. The results showed nearly doubled survival compared to standard-of-care chemotherapy, reinforcing its potential as a chemotherapy-free treatment option in this difficult-to-treat patient population. The findings build on earlier Stage 1 data where gotistobart reduced the risk of death by 54% versus docetaxel and extended median overall survival. BioNTech is now awaiting pivotal Stage 2 results, which could significantly impact regulatory approval prospects and validate its broader transition from a primarily COVID-19 vaccine company to a multi-product oncology business. The success of gotistobart supports the credibility of BioNTech's larger pipeline, including over 14 ongoing pivotal trials. The drug’s potential commercialization may unlock new revenue streams for the firm and improve its long-term earnings profile beyond reliance on pandemic-related vaccine sales.
Tickers: $BNTX
Topics: BioNTech clinical trial results gotistobart lung cancer treatment Phase 3 trials